Navigation Links
Strategic Agreement Launches Novel Drug Development Model
Date:9/7/2012

strategy prior to seeking partnerships to bring these market-tested proprietary compounded drug formulations to market. We believe this agreement is a win not only for our two companies, but for the pharmaceutical industry and the patients that it serves."

About Imprimis Pharmaceuticals, Inc.

Imprimis Pharmaceuticals is a specialty pharmaceutical company developing non-invasive, topically delivered products. Its innovative, patented Accudel cream formulation technology is designed to enable highly targeted site-specific treatment. Impracor, its lead pain-product candidate, uses the Accudel platform technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug, through the skin directly into the underlying tissues, where the drug exerts its localized anti-inflammatory and analgesic effects. It intends to leverage the Accudel platform technology to expand and create a portfolio of topical products for a variety of indications. The Imprimis Pharmaceuticals, Inc. website is currently under construction and is expected to launch in September 2012.

About Professional Compounding Centers of America, Inc. (PCCA)

PCCA is the independent compounding pharmacist's complete resource for quality chemicals, equipment, ACPE-accredited training and education, pharmacy software, clinical and business consulting. Its membership includes more than 3,900 independent community-pharmacists in the United States, Canada, Australia and other countries around the world. PCCA's mission is to strengthen the role, position and skills of member compounding pharmacists so they can meet the unique healthcare needs of patients through exceptional service, high-quality products, shared innovations and education.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be co
'/>"/>

SOURCE Imprimis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
3. Herborium Announces Continuing Progress In Key Strategic Initiatives
4. Amendia, Inc. and Medline Industries, Inc. Announce Investment and Strategic Business Alliance
5. UBM Canon, the Global MedTech Authority, Announces Strategic Alliance with ITG Market Research, a Preeminent Industry Research Organization
6. Watson to Present at the Sanford C. Bernstein 28th Annual Strategic Decisions Conference
7. VitaTech Adds New Capacity for Production and Customer Interface, Attributes Growth to Strategic Customer Partnerships
8. Elekta and The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital Sign Strategic Alliance to Further Cancer Research
9. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
10. Medifast Announces International Expansion Into Mexico Through Strategic Partnership with Medix
11. Dehaier Medical Announces Strategic Mutual Cooperation Agreement with HEYER Medical AG
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... the sale to Galderma of all rights to Restylane, ... Valeant for $1.4 billion in cash, pursuant to the ... its acquisition of Galderma. "We are ... a company that is firmly committed to the aesthetic ...
(Date:7/10/2014)... , July 10, 2014  Decision Resources Group ... infectious disease (ID) specialists are willing to prescribe ... (oritavancin) for use as OPAT, approximately two-thirds of ... agents to their hospital inpatients. However, our findings ... patients are initiated on OPAT following hospital discharge, ...
(Date:7/10/2014)... WOONSOCKET, R.I. , July 10, 2014 CVS ... its board of directors has approved a quarterly dividend of ... The dividend is payable on August 1, 2014, to holders ... Caremark CVS Caremark is dedicated to helping ... integrated pharmacy company in the United States ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... ThermoGenesis Corp. (NASDAQ: KOOL ), a ... and administration of cell therapies, today said that it ... Platform (AXP) used for the processing of cord blood. ... in the country later this year. "We ...
... Mass., May 22, 2012  Halo Therapeutics, LLC, a ... fibrotic diseases, announced today that it has received ... serving the muscular dystrophy patient community. Halo will ... study of HT-100, its lead drug candidate for ...
Cached Medicine Technology:ThermoGenesis Announces Axp Approval In Thailand 2ThermoGenesis Announces Axp Approval In Thailand 3Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100 2Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100 3
(Date:7/10/2014)... 2014 (HealthDay News) -- Teens who are sensitive to ... to develop emotional symptoms such as anxiety and depression, ... these that may exacerbate issues teens experience after concussion ... in making decisions about when to return to play ... athletes," study authors Lisa Koehl and Dong Han, of ...
(Date:7/10/2014)... HealthDay Reporter THURSDAY, July 10, 2014 ... use of calorie information on menus, if it,s available, to ... U.S. study. Women in particular review the menu labeling, ... with the U.S. Centers for Disease Control and Prevention. ... to help choose their meal, compared with just under half ...
(Date:7/10/2014)... with a microchip-based device developed at the Massachusetts General ... MGH Cancer Center can be cultured to establish cell ... the July 11 issue of Science , an ... reflect a tumor,s genetic mutation over time and changing ... culture cells from the blood that represent those present ...
(Date:7/10/2014)... Human Services (HHS) has announced a three-year grant to ... totaling $4.7 million to support a new national model ... , Titled "Evidence-Conformant Oncology Care," the project will ... care for adult cancer patients with late-stage disease, significant ... , "We believe that the best cancer ...
(Date:7/10/2014)... Katerina Alba,s research at the University of Huddersfield could ... most popular emulsion-based food products such as butter, ... starting to gain an international profile for her work. ... food science at the University and now she has ... her supervisor, Dr Vassilis Kontogiorgos, she is investigating the ...
Breaking Medicine News(10 mins):Health News:Some Teens May Face Emotional Problems After Concussion 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 3Health News:Cultured CTCs reveal genetic profile, potential drug susceptibility of breast cancer cells 2Health News:Cultured CTCs reveal genetic profile, potential drug susceptibility of breast cancer cells 3Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3Health News:World interest in research work on the benefits of the Okra plant 2
... /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals,a developer and manufacturer of ... its financial results for the first quarter,ended March ... the first,quarter of 2008, as compared with $5.2 ... in the first quarter 2008 include wound care ...
... DALLAS, May 6 Claimsnet.com inc. (OTC,Bulletin Board: ... healthcare industry, today reported,its results for the first quarter ... the quarter ended March 31, 2008, the Company reported ... for the first quarter,of 2007., Expenses overall, comprised ...
... U.S. college students are smoking tobacco using waterpipes or ... according to a new study led by a Virginia Commonwealth ... prevalence and perceptions related to waterpipe tobacco smokers and are ... Health. The article is also featured in an editorial in ...
... alleviate the plaguing symptoms of allergies ... and asthma, ... allergies or asthma while outdoors, but why deal with irritating,triggers in your home? ... focus on more important things, not on your,symptoms., Try to prevent as ...
... Acquisition of dermal filler product enhances company,s aesthetic ... Stiefel Laboratories, Inc.,the world,s largest independent pharmaceutical company ... ABR Invent and ABR,Development, developers of the dermal ... of ABR Invent and ABR Development,through a definitive ...
... mole develops into melanoma by showing the interaction of ... The Penn State scientists also demonstrate that therapeutic ... effectively treat this deadly form of cancer. , "We ... Akt3 communicate with one another in a mole, ...
Cached Medicine News:Health News:NUCRYST Announces First Quarter 2008 Financial Results 2Health News:NUCRYST Announces First Quarter 2008 Financial Results 3Health News:NUCRYST Announces First Quarter 2008 Financial Results 4Health News:NUCRYST Announces First Quarter 2008 Financial Results 5Health News:NUCRYST Announces First Quarter 2008 Financial Results 6Health News:NUCRYST Announces First Quarter 2008 Financial Results 7Health News:Claimsnet.com Reports First Quarter 2008 Results 2Health News:Claimsnet.com Reports First Quarter 2008 Results 3Health News:Waterpipe smoking on college campuses may contribute to growing public health problem 2Health News:Double Trouble: Fight Allergy and Asthma in Your Home 2Health News:Stiefel Laboratories, Inc. Acquires ABR Invent and ABR Development 2Health News:Stiefel Laboratories, Inc. Acquires ABR Invent and ABR Development 3Health News:Scientists identify interacting proteins key to melanoma development, treatment 2Health News:Scientists identify interacting proteins key to melanoma development, treatment 3
... endoscope is the first Video ... instrument incorporates a 2.0mm instrument ... insertion tube. The slim size ... easy introduction even through areas ...
... Used for temporary internal drainage from ... Supplied sterile in peel-open packages. Intended ... is advised; C-Flex® and Sof-Flex® stents ... six (6) months; silicone stents must ...
... internal drainage from the ureteropelvic junction to ... for ease of placement and patient compliance. ... for repositioning and ease of removal. AQ® ... that when activated, attracts and holds water ...
... Double Pigtail Ureteral Stents have an ... maximizes migration. They also feature unique ... cost savings. Each Classic Double PigTail ... Double PigTail Ureteral Stent with attached ...
Medicine Products: